Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment.
Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment.
复制标题
区分从下一次放射性碘治疗中生化获益的远处转移性分化型甲状腺癌患者
DOI：
10.3389/fendo.2020.587315
复制
发表时间：
2020
影响因子：
5.2
通讯作者：
Chen L
中科院分区：
文献类型：
--
作者：
Sa R;Cheng L;Jin Y;Fu H;Shen Y;Chen L
Background Repeated radioiodine (131I) treatment (RT) are commonly performed in patients with 131I-avid distant metastatic differentiated thyroid cancer (DM-DTC), but more precise indications remain indeterminate. This prospective study was conducted to explore predictors for biochemical response (BR) to next RT. Methods Totally thyroidectomized patients with 131I-avid DM-DTC demonstrated by initial post-therapeutic whole body scan (Rx-WBS) were consecutively recruited. Repeated RTs were performed at a fixed dose and a fixed interval, which was terminated once a decline in thyroid stimulating hormone-suppressed thyroglobulin (Tgon) could not be achieved or Rx-WBS was negative. BR was evaluated by change rate of Tgon level (ΔTgon%). Results After exclusion of 27 ineligible courses, a total of 166 neighboring course pairs from 77 patients were established and utilized. Univariate and multivariate analyses showed that the maximum target/background ratio (T/Bmax) on the whole body scan and ΔTgon% derived from the former RT were independently associated to the latter one. In predicting biochemical remission, the positive predictive value (PPV) and negative predictive value (NPV) of T/Bmax at the cut-off value of 8.1 were 79.1% and 84.0%, respectively; whereas the PPV and NPV of ΔTgon% at the cut-off value of 25.3% were 70.8% and 77.1%, respectively. Notably, the PPV of combined T/Bmax ≥ 8.1 and ΔTgon% ≥ 25.3% increased to 87.7%; while the NPV of T/Bmax ≥ 8.1 or ΔTgon% ≥ 25.3% reached as high as 97.7%. Conclusions This study revealed that combined use of the latest RT-derived T/Bmax and ΔTgon% may efficiently identify biochemical responders/non-responders to next RT, warranting management optimization of patients with 131I-avid DM-DTC.
登录
查看更多内容
影响因子：
1.7
作者：
Califano, Ines;Deutsch, Susana;Lowenstein, Alicia;Cabezon, Carmen;Pitoia, Fabian
通讯作者：
Pitoia, Fabian
影响因子：
9.3
作者：
Hesselink, Esther N. Klein;Brouwers, Adrienne H.;Links, Thera P.
通讯作者：
Links, Thera P.
DOI：
10.1007/s00259-005-1929-2
发表时间：
2006-02-01
影响因子：
9.1
作者：
Pace, L;Klain, M;Salvatore, M
通讯作者：
Salvatore, M
影响因子：
5.2
作者：
Klain, Michele;Pace, Leonardo;Cuocolo, Alberto
通讯作者：
Cuocolo, Alberto
影响因子：
5.8
作者：
Qiu, Zhong-Ling;Song, Hong-Jun;Luo, Quan-Yong
通讯作者：
Luo, Quan-Yong